TH2-polarized CD4+ T Cells and macrophages limit efficacy of radiotherapy

Stephen L. Shiao, Brian Ruffell, David G. De Nardo, Bruce A. Faddegon, Catherine C. Park, Lisa Coussens

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

Radiotherapy and chemotherapy following surgery are mainstays of treatment for breast cancer. Although multiple studies have recently revealed the significance of immune cells as mediators of chemotherapy response in breast cancer, less is known regarding roles for leukocytes as mediating outcomes following radiotherapy. To address this question, we utilized a syngeneic orthotopic murine model of mammary carcinogenesis to investigate if response to radiotherapy could be improved when select immune cells or immune-based pathways in the mammary microenvironment were inhibited. Treatment of mammary tumor-bearing mice with either a neutralizing mAb to colony-stimulating factor-1 (CSF-1) or a small-molecule inhibitor of the CSF-1 receptor kinase (i.e., PLX3397), resulting in efficient macrophage depletion, significantly delayed tumor regrowth following radiotherapy. Delayed tumor growth in this setting was associated with increased presence of CD8+ T cells and reduced presence of CD4+ T cells, the main source of the TH2 cytokine IL4 in mammary tumors. Selective depletion of CD4+ T cells or neutralization of IL4 in combination with radiotherapy phenocopied results following macrophage depletion, whereas depletion of CD8+ T cells abrogated improved response to radiotherapy following these therapies. Analogously, therapeutic neutralization of IL4 or IL13, or IL4 receptor alpha deficiency, in combination with the chemotherapy paclitaxel, resulted in slowed primary mammary tumor growth by CD8+ T-cell-dependent mechanisms. These findings indicate that clinical responses to cytotoxic therapy in general can be improved by neutralizing dominant TH2-based programs driving protumorigenic and immune-suppressive pathways in mammary (breast) tumors to improve outcomes.

Original languageEnglish (US)
Pages (from-to)518-525
Number of pages8
JournalCancer immunology research
Volume3
Issue number5
DOIs
StatePublished - May 1 2015

Fingerprint

Radiotherapy
Macrophages
Breast Neoplasms
T-Lymphocytes
Interleukin-4
Macrophage Colony-Stimulating Factor
Breast
Colony-Stimulating Factor Receptors
Interleukin-4 Receptors
Therapeutics
Drug Therapy
Interleukin-13
Growth
Paclitaxel
Combination Drug Therapy
Neoplasms
Carcinogenesis
Leukocytes
Phosphotransferases
Cytokines

ASJC Scopus subject areas

  • Cancer Research
  • Immunology

Cite this

TH2-polarized CD4+ T Cells and macrophages limit efficacy of radiotherapy. / Shiao, Stephen L.; Ruffell, Brian; De Nardo, David G.; Faddegon, Bruce A.; Park, Catherine C.; Coussens, Lisa.

In: Cancer immunology research, Vol. 3, No. 5, 01.05.2015, p. 518-525.

Research output: Contribution to journalArticle

Shiao, Stephen L. ; Ruffell, Brian ; De Nardo, David G. ; Faddegon, Bruce A. ; Park, Catherine C. ; Coussens, Lisa. / TH2-polarized CD4+ T Cells and macrophages limit efficacy of radiotherapy. In: Cancer immunology research. 2015 ; Vol. 3, No. 5. pp. 518-525.
@article{ed3b45a28c0e40998452110cafde88e3,
title = "TH2-polarized CD4+ T Cells and macrophages limit efficacy of radiotherapy",
abstract = "Radiotherapy and chemotherapy following surgery are mainstays of treatment for breast cancer. Although multiple studies have recently revealed the significance of immune cells as mediators of chemotherapy response in breast cancer, less is known regarding roles for leukocytes as mediating outcomes following radiotherapy. To address this question, we utilized a syngeneic orthotopic murine model of mammary carcinogenesis to investigate if response to radiotherapy could be improved when select immune cells or immune-based pathways in the mammary microenvironment were inhibited. Treatment of mammary tumor-bearing mice with either a neutralizing mAb to colony-stimulating factor-1 (CSF-1) or a small-molecule inhibitor of the CSF-1 receptor kinase (i.e., PLX3397), resulting in efficient macrophage depletion, significantly delayed tumor regrowth following radiotherapy. Delayed tumor growth in this setting was associated with increased presence of CD8+ T cells and reduced presence of CD4+ T cells, the main source of the TH2 cytokine IL4 in mammary tumors. Selective depletion of CD4+ T cells or neutralization of IL4 in combination with radiotherapy phenocopied results following macrophage depletion, whereas depletion of CD8+ T cells abrogated improved response to radiotherapy following these therapies. Analogously, therapeutic neutralization of IL4 or IL13, or IL4 receptor alpha deficiency, in combination with the chemotherapy paclitaxel, resulted in slowed primary mammary tumor growth by CD8+ T-cell-dependent mechanisms. These findings indicate that clinical responses to cytotoxic therapy in general can be improved by neutralizing dominant TH2-based programs driving protumorigenic and immune-suppressive pathways in mammary (breast) tumors to improve outcomes.",
author = "Shiao, {Stephen L.} and Brian Ruffell and {De Nardo}, {David G.} and Faddegon, {Bruce A.} and Park, {Catherine C.} and Lisa Coussens",
year = "2015",
month = "5",
day = "1",
doi = "10.1158/2326-6066.CIR-14-0232",
language = "English (US)",
volume = "3",
pages = "518--525",
journal = "Cancer immunology research",
issn = "2326-6066",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - TH2-polarized CD4+ T Cells and macrophages limit efficacy of radiotherapy

AU - Shiao, Stephen L.

AU - Ruffell, Brian

AU - De Nardo, David G.

AU - Faddegon, Bruce A.

AU - Park, Catherine C.

AU - Coussens, Lisa

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Radiotherapy and chemotherapy following surgery are mainstays of treatment for breast cancer. Although multiple studies have recently revealed the significance of immune cells as mediators of chemotherapy response in breast cancer, less is known regarding roles for leukocytes as mediating outcomes following radiotherapy. To address this question, we utilized a syngeneic orthotopic murine model of mammary carcinogenesis to investigate if response to radiotherapy could be improved when select immune cells or immune-based pathways in the mammary microenvironment were inhibited. Treatment of mammary tumor-bearing mice with either a neutralizing mAb to colony-stimulating factor-1 (CSF-1) or a small-molecule inhibitor of the CSF-1 receptor kinase (i.e., PLX3397), resulting in efficient macrophage depletion, significantly delayed tumor regrowth following radiotherapy. Delayed tumor growth in this setting was associated with increased presence of CD8+ T cells and reduced presence of CD4+ T cells, the main source of the TH2 cytokine IL4 in mammary tumors. Selective depletion of CD4+ T cells or neutralization of IL4 in combination with radiotherapy phenocopied results following macrophage depletion, whereas depletion of CD8+ T cells abrogated improved response to radiotherapy following these therapies. Analogously, therapeutic neutralization of IL4 or IL13, or IL4 receptor alpha deficiency, in combination with the chemotherapy paclitaxel, resulted in slowed primary mammary tumor growth by CD8+ T-cell-dependent mechanisms. These findings indicate that clinical responses to cytotoxic therapy in general can be improved by neutralizing dominant TH2-based programs driving protumorigenic and immune-suppressive pathways in mammary (breast) tumors to improve outcomes.

AB - Radiotherapy and chemotherapy following surgery are mainstays of treatment for breast cancer. Although multiple studies have recently revealed the significance of immune cells as mediators of chemotherapy response in breast cancer, less is known regarding roles for leukocytes as mediating outcomes following radiotherapy. To address this question, we utilized a syngeneic orthotopic murine model of mammary carcinogenesis to investigate if response to radiotherapy could be improved when select immune cells or immune-based pathways in the mammary microenvironment were inhibited. Treatment of mammary tumor-bearing mice with either a neutralizing mAb to colony-stimulating factor-1 (CSF-1) or a small-molecule inhibitor of the CSF-1 receptor kinase (i.e., PLX3397), resulting in efficient macrophage depletion, significantly delayed tumor regrowth following radiotherapy. Delayed tumor growth in this setting was associated with increased presence of CD8+ T cells and reduced presence of CD4+ T cells, the main source of the TH2 cytokine IL4 in mammary tumors. Selective depletion of CD4+ T cells or neutralization of IL4 in combination with radiotherapy phenocopied results following macrophage depletion, whereas depletion of CD8+ T cells abrogated improved response to radiotherapy following these therapies. Analogously, therapeutic neutralization of IL4 or IL13, or IL4 receptor alpha deficiency, in combination with the chemotherapy paclitaxel, resulted in slowed primary mammary tumor growth by CD8+ T-cell-dependent mechanisms. These findings indicate that clinical responses to cytotoxic therapy in general can be improved by neutralizing dominant TH2-based programs driving protumorigenic and immune-suppressive pathways in mammary (breast) tumors to improve outcomes.

UR - http://www.scopus.com/inward/record.url?scp=84962208716&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962208716&partnerID=8YFLogxK

U2 - 10.1158/2326-6066.CIR-14-0232

DO - 10.1158/2326-6066.CIR-14-0232

M3 - Article

C2 - 25716473

AN - SCOPUS:84962208716

VL - 3

SP - 518

EP - 525

JO - Cancer immunology research

JF - Cancer immunology research

SN - 2326-6066

IS - 5

ER -